Janssen vs Otsuka expects domestic competition for long-acting schizophrenia drugss

In the schizophrenia treatment market, competition to introduce long-acting injections has become active.

Leading pharmaceutical companies in the field, Janssen and Otsuka, have released follow-up products in series.

Janssen is currently going through the approval procedure of the upgraded version of ‘Invega Sustenna(paliperidone, once-monthly administration),’ the only domestic long-acting i...